For personal use only

10 November 2026

Australian Compounding Agreement Signed for Men's Health Range

Highlights

- EVE has signed a binding Master Compounding and Profit Share Agreement to commercialise its proprietary men's sexual health range in Australia.
- Targets the large and growing men's sexual health market, which patients increasingly access through telehealth channels.
- Capital-light model: EVE supplies its proprietary, patent-pending technology, and the pharmacy partner compounds and dispenses the product, providing an additional revenue pathway.
- EVE is entitled to 75% of the profit available for distribution after direct costs of compounding and delivery.
- EVE retains full ownership of its patent-pending technology and related intellectual property.
- A broader portfolio of potential compoundable products, built on EVE's technology, to be assessed.

EVE Health Group Limited (ASX: EVE, EVE or the **Company)** is pleased to announce that it has entered into a binding Master Compounding and Profit Share Agreement (**Agreement**) with Optimal Pharmacy Plus Stafford (**Optimal**), an important step in commercialising EVE's proprietary technology in the Australian men's health market.

Men's sexual health is a large and growing market, and one that patients increasingly access through telehealth. The Agreement provides EVE with a pathway to supply its proprietary range to patients through a pharmacy-led model. An Australian study of more than 100,000 men aged 45 and over found that around 61% reported some degree of erectile dysfunction, and around one in three reported moderate or complete erectile dysfunction.[1] Globally, erectile dysfunction was projected to affect around 322 million men by 2025,[2] and the global erectile dysfunction treatment market is estimated at approximately US$5.7 billion in 2026.[3]

The structure is capital-light, EVE supplies its formulation technology and the pharmacy partner compounds, dispenses and delivers the product, so EVE can earn revenue from its intellectual

[1] Weber MF, et al. Risk factors for erectile dysfunction in a cohort of 108 477 Australian men. Medical Journal of Australia, 2013; 199(2): 107–111. https://doi.org/10.5694/mja12.11548. Figures are self-reported (Sexual Health Inventory for Men) for men aged 45 and over in the NSW 45 and Up Study with no prior prostate cancer diagnosis: mild 25.1%, moderate 18.8%, complete 16.8%.
[2] Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU International, 1999; 84(1): 50–56. https://pubmed.ncbi.nlm.nih.gov/10444124/
[3] Coherent Market Insights, Erectile Dysfunction Treatment Market Size and Share Analysis: Growth Trends and Forecasts (2026–2033), published 28 April 2026 (estimated value of US$5.67 billion in 2026). https://www.coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200

property without the cost and time of building its own compounding operation, while keeping the option to pursue a registered product in the future.

The range is based on EVE's patent-pending nano-emulsion technology, designed to treat both erectile dysfunction and premature ejaculation, two conditions that commonly occur together. EVE retains ownership of the formulation and all related intellectual property, including any improvements made under the Agreement.

The Agreement is separate from, and does not affect, the Company's Libbo® vardenafil oral soluble film program, which continues along its planned bioequivalence and registration pathway.

The Company considers that, subject to commercial agreement and applicable regulatory requirements, the same model may support further compounded products over time, and the ability to access international markets through similar channels.

Material terms of the Agreement

EVE supplies the technology, technical know-how and commercial support. Optimal is responsible for sourcing ingredients, compounding, dispensing and delivery. First supply is subject to conditions, including completion of technology transfer and validation.

Profit available for distribution is shared 75% to EVE and 25% to Optimal. It is calculated as net patient revenue (excluding GST, refunds and chargebacks) less the direct costs of compounding and delivery, being ingredients, packaging, delivery and a fixed per-unit labour rate, with no margin or mark-up and with all rebates and savings passed through. EVE pays support fees to telehealth partners for the telehealth services they provide, and these are met from EVE's 75% share. There are no upfront payments or fixed fees payable by EVE under the Agreement.

The initial term is two years from first supply, after which the Agreement renews automatically for successive 12-month periods unless either party gives 90 days' notice before the end of the current term. Either party may terminate on 30 days' notice for an unremedied material breach, or immediately on insolvency or loss of a necessary licence or approval. EVE may also terminate if first supply has not occurred within three months of signing (other than due to EVE's default), and either party may terminate if a change in law or regulatory direction makes the arrangement unlawful and the parties cannot agree changes within 30 days.

Optimal's appointment is exclusive in Australia for the initial products from first supply, and Optimal must not compound or supply competing formulations.

The Agreement otherwise contains terms customary for an agreement of this nature, including quality, safety reporting, confidentiality and intellectual property protection provisions.

The Agreement does not include minimum volumes or guaranteed revenue. The Company is not yet able to estimate the revenue the Agreement may generate, which will depend on the timing of first supply, prescribing decisions by independent clinicians, patient demand, pricing and costs.

EVE Chief Executive Officer, Ben Rohr, said: *"This Agreement is an important milestone for EVE. We are taking our proprietary, patent-pending technology to market in Australia through a capital-light model, with a strong pharmacy partner that will support supply. We keep full ownership of our IP, we*

For personal use only

establish a pathway to revenue, and we retain the option to pursue a registered product as well. We see this as the first step in unlocking value from our formulation technology."

Next steps

EVE will now work with Optimal to complete the readiness steps for first supply and engage telehealth partners to reach patients. Prescribing decisions will remain with independent clinicians, with each product compounded for an individual patient against a valid prescription.

Compounded medicines are prepared by a pharmacist for an individual patient against a valid prescription. They are not entered on the Australian Register of Therapeutic Goods and have not been assessed by the Therapeutic Goods Administration for safety, quality or efficacy.

This announcement was authorised for release by the Board of Directors of EVE Health Group Limited.

Company enquiries
+61 8 6465 5500
info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The Company's lead assets include Dyspro®, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo®, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

EVE is building a vertically integrated health platform that combines proprietary pharmaceutical products with digital education, patient engagement and prescribing pathways. Through its dedicated information platforms, ReclaimMyCycle.com (women's health) and StiffIssue.com (men's health), the Company provides condition-focused education, reduces stigma and supports earlier engagement with appropriate care. These platforms integrate with telehealth and pharmacy fulfilment networks to enable responsible, scalable access to treatment within a regulated healthcare framework.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

For personal use only